Minimally Invasive Therapy for
Abnormal Aortic Aneurysm (AAA)
Vision
BiFlow’s vision is to replace abdominal aorta aneurysm (AAA) surgeries by regular endovascular repairing.
BiFlow Medical developed a mechanism that integrates two unique stents, Side-Branch Stent and Extension Graft Stent, for those diagnosed with critical abdominal aortic aneurysms (AAA) situation which can be repaired only by surgery.
BiFlow’s side-branch stent will enable an extension of the Aorta Graft Stent, and enable blood flow through the renal artery and by that increase the number of patients who can undergo EVAR.
The Market
Abdominal Aortic Aneurysm (AAA) affects 2% of the population in the U.S. and 8% of those over 65 with much higher incidence in smokers. Ruptured AAA’s cause 15,000 deaths in the U.S. each year (10th leading cause of death in men).
600,000 new cases diagnosed each year worldwide. 100,000 undergo surgery while most patients will not undergo any procedure due to high risk for ruptured aneurysm.
Endovascular Aneurysm Repair (EVAR) market is growing rapidly to overtake conventional surgery.
50,000 EVAR procedures in US (estimated in 2020).
Technology & Products
The company is developing a state-of-the-art, IP protected, novel Nitinol side branch stent and Graft-stent extension.
The renal artery stent penetrates the main graft-stent extension installed in the main artery (aorta) and opens up for total sealing. This enables total endovascular AAA repairing, easier, shorter and less expensive procedures for patients with a minimum of 13 mm adequate “neck” length (60% of patients).
The stents are easy to deploy and impose significantly lower risk to the patient.
Haim Ackerman (B.Sc.)
Co-founder, former CEO and BOD member
Entrepreneur with 25 years’ experience in top managerial positions in the high-tech and Medical Device industries. Founder, Chairman and CEO at Forconti Medical Ltd. Served as VP Special Projects at Given Imaging (Medtronic). Founder of STRIMM, a $50M budget consortium. Haim holds Bachelor’s degree (BSc) in Industrial Engineering and Management from the Technion.
Ofer Bogomoletz (B.Sc.)
C.E.O.
30 years experience from R&D to C.E.O. with China (Shanghai, Changzhou, Suzhou), Europe and US markets. Founder of a Medical Device start-up. Worked at 2 companies acquired by Johnson & Johnson and Boston Scientific.
Yaron Cherny (LLM, B.A.)
BOD
Results-oriented Business Development professional in the Life Science field. Ex-Director Biz-Dev Teva Israel, head of business development at Kamada and currently the CEO of ShizimXL–ICB.
Yossi Bornstein
Chairman of the Board
Founder and President of Shizim Group. In the past 35 years, served in key roles in the healthcare industry, and is recognized for his activity both in Israel and abroad. Mr. Bornstein is the founder of multiple successful HealthCare companies and global projects and was the CEO of Bristol Myers Squibb (BMS) in Israel. Mr. Bornstein is a co-founder as well as a member of the Board of Directors at Microbot Medical, Inc. (NASDAQ – MBOT) and XACT Robotics
Varda Leshem
BOD member
Mrs. Leshem joined the BiFlow board of directors as a representing of a group of angel investors that had decided to invest the seed money in BiFlow. Mrs. Leshem is mediator and personal trainer. Holds a bachelor’s degree in humanities.